» Articles » PMID: 25683060

Neurokinin B Administration Induces Hot Flushes in Women

Abstract

Neurokinin B (NKB) is a hypothalamic neuropeptide binding preferentially to the neurokinin 3 receptor. Expression of the gene encoding NKB is elevated in postmenopausal women. Furthermore, rodent studies suggest that NKB signalling may mediate menopausal hot flushes. However, the effects of NKB administration on hot flushes have not been investigated in humans. To address this, we performed a randomised, double-blinded, placebo-controlled, 2-way cross-over study. Ten healthy women were admitted to a temperature and humidity-controlled research unit. Participants received 30 minute intravenous infusions of NKB and vehicle in random order. Symptoms, heart rate, blood pressure, sweating and skin temperature were compared between NKB and vehicle in a double-blinded manner. Eight of ten participants experienced flushing during NKB infusion with none experiencing flushing during vehicle infusion (P = 0.0007). Significant elevations in heart rate (P = 0.0106 vs. pre-symptoms), and skin temperature measured using skin probe (P = 0.0258 vs. pre-symptoms) and thermal imaging (P = 0.0491 vs. pre-symptoms) characteristic of menopausal flushing were observed during hot flush episodes. Our findings provide evidence that NKB administration can cause hot flushes in women. Further studies are required to determine if pharmacological blockade of NKB signalling could inhibit hot flushes during the menopause and during treatment for sex-steroid dependent cancers.

Citing Articles

The aged female rhesus macaque as a translational model for human menopause and hormone therapy.

Kohama S, Urbanski H Horm Behav. 2024; 166:105658.

PMID: 39531811 PMC: 11602343. DOI: 10.1016/j.yhbeh.2024.105658.


The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.

Patel B, Koysombat K, Mills E, Tsoutsouki J, Comninos A, Abbara A Endocr Rev. 2023; 45(1):30-68.

PMID: 37467734 PMC: 10765167. DOI: 10.1210/endrev/bnad023.


Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.

Hassan F, Saleem A, Samuel S, Sarfraz Z, Sarfraz A, Sarfraz M Medicine (Baltimore). 2023; 102(23):e33978.

PMID: 37335635 PMC: 10256371. DOI: 10.1097/MD.0000000000033978.


The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.

Wright A, Beaudoin F, McQueen R, Yeung K, Moradi A, Herron-Smith S J Manag Care Spec Pharm. 2023; 29(6):692-698.

PMID: 37276043 PMC: 10387909. DOI: 10.18553/jmcp.2023.29.6.692.


Essential Role of Histidine for Rapid Copper(II)-Mediated Disassembly of Neurokinin B Amyloid.

Jayawardena B, Peacey L, Gamsjaeger R, Jones C Biomolecules. 2022; 12(11).

PMID: 36358935 PMC: 9687585. DOI: 10.3390/biom12111585.


References
1.
Freedman R, Dinsay R . Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertil Steril. 2000; 74(1):20-3. DOI: 10.1016/s0015-0282(00)00563-x. View

2.
Bahr D, Webster J, Grady D, Kronenberg F, Creasman J, Macer J . Miniature ambulatory skin conductance monitor and algorithm for investigating hot flash events. Physiol Meas. 2014; 35(2):95-110. PMC: 3951394. DOI: 10.1088/0967-3334/35/2/95. View

3.
Carpenter J, Johnson D, Wagner L, Andrykowski M . Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum. 2002; 29(3):E16-25. DOI: 10.1188/02.ONF.E16-E25. View

4.
Lecci A, Maggi C . Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets. 2003; 7(3):343-62. DOI: 10.1517/14728222.7.3.343. View

5.
Carpenter J, Gilchrist J, Chen K, Gautam S, Freedman R . Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause. 2004; 11(4):375-81. DOI: 10.1097/01.gme.0000113848.74835.1a. View